Prosecution Insights
Last updated: April 19, 2026
Application No. 18/249,401

BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

Non-Final OA §102
Filed
Apr 18, 2023
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Korea Institute Of Science And Technology
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-5 are pending. Claims 1-5 are rejected. Priority This is a 35 U.S.C. 371 National Stage Filing of International Application No. PNG media_image1.png 23 199 media_image1.png Greyscale , which claims priority under 35 U.S.C. 119(a-d) to PNG media_image2.png 20 313 media_image2.png Greyscale . Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d). Information Disclosure Statements The Information Disclosure Statements (IDS) submitted on 4/18/2023, 8/6/2024, and 12/24/2024 were considered by the Examiner. Election of Species Applicant’s election without traverse of compound 30 of instant claim 4: PNG media_image3.png 122 169 media_image3.png Greyscale , in the reply filed on 9/15/2025 is acknowledged. The elected species is not allowable. Incidental to the search of the elected species, prior art over non-elected species was discovered and, in the interest of compact prosecution, is presented below. Claim Objections Claim 4 is objected to because of the following informalities: There should be an “or” between the last two compounds on p. 7. Appropriate correction is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-5 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 193070-47-2 (which entered STN database on 8/26/1997). Regarding instant claim 1, CAS Registry No. 193070-47-2 is drawn to the following structure: PNG media_image4.png 160 261 media_image4.png Greyscale , which is embraced by a compound of instant Structural Formula 2: PNG media_image5.png 144 201 media_image5.png Greyscale , wherein R5-R8 = H. Regarding instant claims 2-3, CAS Registry No. 193070-47-2 is embraced by a compound of instant Structural Formula 4: PNG media_image6.png 177 198 media_image6.png Greyscale , wherein R13- R16 = H. Regarding instant claim 4, CAS Registry No. 193070-47-2 is identical to compound 23 on p. 6: PNG media_image7.png 149 170 media_image7.png Greyscale . Regarding instant claim 5, which depends from instant claim 1, the limitation of a pharmaceutically acceptable salt is not a requirement and therefore does not need to be addressed. The following limitation of instant claims 1-5, “for inhibiting the activity of the 5-HT7 serotonin receptor”, is part of the preamble. “If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Shoes by Firebug LLC v. Stride Rite Children’s Grp., LLC, 962 F.3d 1362, 2020 USPQ2d 10701 (Fed. Cir. 2020)”. See MPEP 2111.02(II). Therefore, this limitation does not need to be addressed by the prior art. Claim(s) 1-5 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 1448808-50-1 (which entered the STN database on 8/21/2013). Regarding instant claim 1, CAS Registry No. 1448808-50-1 is drawn to the following structure: PNG media_image8.png 169 239 media_image8.png Greyscale , which is embraced by a compound of instant Structural Formula 2: PNG media_image5.png 144 201 media_image5.png Greyscale , wherein R5 – R7 = H and R8 = C1 alkoxy group. Regarding instant claims 2-3, CAS Registry No. 1448808-50-1 is embraced by a compound of instant Structural Formula 4: PNG media_image6.png 177 198 media_image6.png Greyscale , wherein R13- R15 = H and R16 = C1 alkoxy. Regarding instant claim 4, CAS Registry No. 1448808-50-1 is identical to the structure of the instant elected species, compound 30 on p. 6: PNG media_image9.png 126 179 media_image9.png Greyscale . Regarding instant claim 5, which depends from instant claim 1, the limitation of a pharmaceutically acceptable salt is not a requirement and therefore does not need to be addressed. The following limitation of instant claims 1-5, “for inhibiting the activity of the 5-HT7 serotonin receptor”, is part of the preamble. “If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Shoes by Firebug LLC v. Stride Rite Children’s Grp., LLC, 962 F.3d 1362, 2020 USPQ2d 10701 (Fed. Cir. 2020)”. See MPEP 2111.02(II). Therefore, this limitation does not need to be addressed by the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph McKane can be reached at 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626 /JOSEPH K MCKANE/Supervisory Patent Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Apr 18, 2023
Application Filed
Oct 20, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month